Renhe Pharmacy Co.,Ltd Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Operating Revenue	3,678	3,995	4,927	5,075	4,841	4,211
Other Revenue	79.63	79.63	105.17	78.56	94.45	67.03
Revenue	3,758	4,075	5,032	5,153	4,936	4,278
Revenue Growth (YoY)	-13.89%	-19.02%	-2.35%	4.41%	15.38%	-6.62%
Cost of Revenue	2,379	2,542	3,187	3,308	3,071	2,609
Gross Profit	1,379	1,533	1,845	1,845	1,865	1,669
Selling, General & Admin	649.07	748.38	804.72	864.65	850.05	799.93
Research & Development	47.05	43.85	46.36	50.54	52.14	39.79
Other Operating Expenses	56.43	40.84	46	44.46	37.76	35.77
Operating Expenses	785.25	861.67	901	966.32	942.38	877.06
Operating Income	593.68	671.27	943.83	878.95	922.49	791.72
Interest Expense	-0.13	-0.17	-0.35	-0.43	-0.98	-1.42
Interest & Investment Income	93.53	86.33	87.92	70.49	88.18	82.09
Currency Exchange Gain (Loss)	-	-	-	-0	-0	-
Other Non Operating Income (Expenses)	-1.6	-3.15	-3.39	-0.69	-2.01	-13.9
EBT Excluding Unusual Items	685.48	754.29	1,028	948.33	1,008	858.49
Impairment of Goodwill	-45	-45	-31.33	-27.89	-	-
Gain (Loss) on Sale of Investments	15.93	16.03	16.83	22.11	-0.03	-0.12
Gain (Loss) on Sale of Assets	3.39	1.37	-0.27	0.34	16.84	0.02
Asset Writedown	-59.71	-60.01	-176.3	-4.53	-1.44	-
Legal Settlements	-2.3	-2.3	-	-	-	-
Other Unusual Items	109.52	110.24	61.91	15.18	11.37	10.39
Pretax Income	707.3	774.62	898.86	953.54	1,034	868.79
Income Tax Expense	186.51	208.03	269.45	242	234.54	194.49
Earnings From Continuing Operations	520.79	566.59	629.41	711.54	799.87	674.29
Minority Interest in Earnings	-75.42	-84.67	-62.15	-137.11	-134.85	-94.11
Net Income	445.37	481.91	567.26	574.43	665.02	580.18
Net Income to Common	445.37	481.91	567.26	574.43	665.02	580.18
Net Income Growth	0.64%	-15.04%	-1.25%	-13.62%	14.62%	7.88%
Shares Outstanding (Basic)	1,377	1,377	1,384	1,401	1,385	1,261
Shares Outstanding (Diluted)	1,395	1,395	1,400	1,401	1,385	1,261
Shares Change (YoY)	-0.34%	-0.34%	-0.08%	1.13%	9.85%	0.84%
EPS (Basic)	0.32	0.35	0.41	0.41	0.48	0.46
EPS (Diluted)	0.32	0.35	0.41	0.41	0.48	0.46
EPS Growth	0.98%	-14.76%	-1.17%	-14.58%	4.35%	6.98%
Free Cash Flow	995.18	271.54	312.92	1,049	277.93	665.69
Free Cash Flow Per Share	0.71	0.20	0.22	0.75	0.20	0.53
Dividend Per Share	0.150	0.150	0.200	0.200	0.100	0.200
Dividend Growth	-25.00%	-25.00%	-	100.00%	-50.00%	100.00%
Gross Margin	36.70%	37.62%	36.66%	35.81%	37.78%	39.01%
Operating Margin	15.80%	16.47%	18.76%	17.06%	18.69%	18.51%
Profit Margin	11.85%	11.83%	11.27%	11.15%	13.47%	13.56%
Free Cash Flow Margin	26.48%	6.66%	6.22%	20.35%	5.63%	15.56%
EBITDA	695.1	787.04	1,079	990.73	1,006	873.92
EBITDA Margin	18.50%	19.31%	21.44%	19.23%	20.37%	20.43%
D&A For EBITDA	101.43	115.77	134.89	111.78	83.15	82.2
EBIT	593.68	671.27	943.83	878.95	922.49	791.72
EBIT Margin	15.80%	16.47%	18.76%	17.06%	18.69%	18.51%
Effective Tax Rate	26.37%	26.86%	29.98%	25.38%	22.67%	22.39%
Revenue as Reported	3,758	4,075	5,032	5,153	4,936	4,278
Advertising Expenses	-	161.72	202.54	217.09	215	168.39

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.